.png){kind=small}
Paul has clinical and scientific expertise in transplant and heart failure, having published over 200 peer-reviewed scientific articles. He has been a serial entrepreneur and founder and Chief Medical Officer of medical device start-up companies, including Ardian; CHF Solutions; ARTritech Med; ROX Med and Advanced Heuristics. Paul has extensive executive experience: he served as a Medical Advisor to Medtronic and Merck Pharmaceutical, and as Entrepreneur-in-Residence at the White House, assigned to the FDA. Paul was a Professor of Medicine and Physiology at The Ohio State University, Loyola and Vice Chair of Medicine at Wayne State University.
Canran received her BS in Biomedical Science from Shanghai Jiao Tong University, where she graduated with first-class honours. She is currently pursuing a PhD degree in Medical Engineering at the California Institute of Technology with a research focus on developing wearable bioelectronics for chronic disease management. She has 18 publications with 7 of them as first/co-first author in the biomedical engineering field. Prior to the graduate program, she worked as an analyst for a healthcare investment bank in China and completed over $80mn overall in fundraising deals for biotech and biopharma startups. She is interested in promoting the clinical translation and commercialisation of biotechnology.
The future potential of mRNA therapeutics and vaccines is constrained by legacy manufacturing methods.
Sensible enables the next generation of mRNA medicines by turning living cells into factories producing abundant, highly stable and non-immunogenic mRNA in a scalable and cost-effective way.
mRNA is typically made via cell-free methods. By leveraging processes in engineered living cells, we produce high-quality mRNA in a cost-efficient and scalable fashion.
long mRNA opens the path towards novel mRNA-based modalities
naturally modified mRNA increases the efficacy of mRNA therapies
cost-effective mRNA manufacturing improves access to mRNA technology
scalable mRNA production strengthens biosecurity and supply chain resilience
We are combining principles of cell engineering, computational biology and precision fermentation to build the cell-based platform for the manufacturing and design of mRNA vaccines and therapeutics.
Our team brings together leading experts in mRNA manufacturing and synthetic biology, with the support of top life science executives and investors.
We are hiring cell engineers, bioprocess engineers, mRNA Quality Control analysts and RNA computational biologists for our Oxford site. The specific job descriptions are coming soon, but you can drop us an email including your CV or resumé.
Sensible Biotechnologies, Inc., an mRNA platform company, has announced a $4.2mn pre-seed round to accelerate the development of its cell-based platform for cost-efficient manufacturing of high-quality mRNA.
Read More
Ginkgo partners up with Sensible Biotechnologies to forge mRNA manufacturing platform
Since the successful, global release of mRNA-based Covid-19 vaccines, the mRNA platform has become a top focus for biopharma companies. Ginkgo Bioworks’ latest partnership looks to further tap the mRNA market.
Read More
Fermentation tanks filled with thousands of liters of growth media and cells have been the picture of therapeutics production for decades.
Read More
Developing a Novel mRNA Manufacturing Platform with Sensible Biotechnologies
Today, we are pleased to announce our partnership with Sensible Biotechnologies to develop an in vivo microbial mRNA manufacturing platform.
Read More
Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform
Sensible Biotechnologies entered into a partnership with Ginkgo Bioworks to develop an in vivo microbial mRNA manufacturing platform.
Read MoreThrough this partnership, Sensible and Ginkgo aim to develop an in vivo alternative to conventional in vitro mRNA production technology.
Read MoreBiomedical Research Center
SlovakAcademy of Sciences
Dubravska cesta 9
845 05 Bratislava
Slovakia
Oxford Brookes Bioinnovation Hub
Headington Campus
Oxford OX3 0BP
United Kingdom
.png)
.png)
